Examination of therapeutic efficacy after changing faricimab for patients with wet age-related macular degeneration using existing anti-VEGF drugs

Examination of therapeutic efficacy after changing faricimab for patients with wet age-related macular degeneration using existing anti-VEGF drugs - Efficacy of treatment after changing faricimab for wet AMD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052582

Enrollment

100

Registered

2023-10-23

Start date

2022-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

wet age-related macular degeneration

Interventions

Intravitreous injection of faricimab for 2 years when needed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)disease duration:regardless 2)Patients who existing anti-VEGF drugs (aflibercept, ranibizumabu or brolucizumab) are used, and vitreous injections are performed every 1-3months in the maintenance phase, and exudation dose not improve for 1 year or more(tolerance), who progress vision loss, who relapses immediately without without injection (dependency), and who do not respond to existing anti-VEGF drug therapy from the initial treatment (non responder). 3)BCVA:0.1-1.0 4)Presence of subretinal hemorrhage, scar or macular fibrosis (<50% lesion area) 5)Patient consent:patients who, after receiving a sufficient explanation before participating in this study, obtained their informed consent by themselves. 6)Outpatien

Exclusion criteria

Exclusion criteria: 1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 4) Active intraocular inflammation 5) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 6) Patient who the doctor in charge judges are ineligible for the study

Design outcomes

Primary

Measure	Time frame
Improvement rate of visual acuity one year after the change of faricimab.	—

Secondary

Measure	Time frame
One year outcome after the change of faricimab:macula dry rate(presence of absence of exudative change), reduction rate of central macular thickness, change rate of subfoveal choroidal thickness, the rate of incidence and enlargement of macular atrophy, and number of administrations	—

Countries

Japan

Contacts

Public ContactRie Osaka

Kagawa Medical University Hospital ophthalmology

osaka.rie@kagawa-u.ac.jp087-898-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026